After observing the FOXM1-AURKB relationship in SCLC, specific AURKB inhibitor Barasertib was tested on SBC-3 cells which showed a very potent effect on this cell line, highlighting the importance of FOXM1-AURKB axis (supplementary Fig. S11A). Here, AURKB is linked to small cell lung carcinoma.